Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

35 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Uninterrupted Dabigatran versus Warfarin for Ablation in Atrial Fibrillation.
Calkins H, Willems S, Gerstenfeld EP, Verma A, Schilling R, Hohnloser SH, Okumura K, Serota H, Nordaby M, Guiver K, Biss B, Brouwer MA, Grimaldi M; RE-CIRCUIT Investigators. Calkins H, et al. Among authors: nordaby m. N Engl J Med. 2017 Apr 27;376(17):1627-1636. doi: 10.1056/NEJMoa1701005. Epub 2017 Mar 19. N Engl J Med. 2017. PMID: 28317415 Free article. Clinical Trial.
Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation.
Cannon CP, Bhatt DL, Oldgren J, Lip GYH, Ellis SG, Kimura T, Maeng M, Merkely B, Zeymer U, Gropper S, Nordaby M, Kleine E, Harper R, Manassie J, Januzzi JL, Ten Berg JM, Steg PG, Hohnloser SH; RE-DUAL PCI Steering Committee and Investigators. Cannon CP, et al. Among authors: nordaby m. N Engl J Med. 2017 Oct 19;377(16):1513-1524. doi: 10.1056/NEJMoa1708454. Epub 2017 Aug 27. N Engl J Med. 2017. PMID: 28844193 Free article. Clinical Trial.
Comparison of uninterrupted anticoagulation with dabigatran etexilate or warfarin in the periprocedural period for atrial fibrillation catheter ablation: Results of the Japanese subgroup of the RE-CIRCUIT trial.
Yoshida Y, Watarai M, Fujii K, Shimizu W, Satomi K, Inden Y, Murakami Y, Murakami M, Iwasa A, Kimura M, Yamada N, Nakagawa T, Nordaby M, Okumura K. Yoshida Y, et al. Among authors: nordaby m. J Arrhythm. 2018 Jan 13;34(2):148-157. doi: 10.1002/joa3.12024. eCollection 2018 Apr. J Arrhythm. 2018. PMID: 29657590 Free PMC article.
Uninterrupted anticoagulation with non-vitamin K antagonist oral anticoagulants in atrial fibrillation catheter ablation: Lessons learned from randomized trials.
Cardoso R, Willems S, Gerstenfeld EP, Verma A, Schilling R, Hohnloser SH, Okumura K, Nordaby M, Brouwer MA, Calkins H. Cardoso R, et al. Among authors: nordaby m. Clin Cardiol. 2019 Jan;42(1):198-205. doi: 10.1002/clc.23120. Epub 2018 Dec 7. Clin Cardiol. 2019. PMID: 30460702 Free PMC article. Review.
Regional differences in patient characteristics and outcomes during uninterrupted anticoagulation with dabigatran versus warfarin in catheter ablation of atrial fibrillation: the RE-CIRCUIT study.
Hohnloser SH, Calkins H, Willems S, Verma A, Schilling R, Okumura K, Nordaby M, Kleine E, Biss B, Gerstenfeld EP; RE-CIRCUIT® investigators. Hohnloser SH, et al. Among authors: nordaby m. J Interv Card Electrophysiol. 2019 Aug;55(2):145-152. doi: 10.1007/s10840-019-00518-x. Epub 2019 Feb 13. J Interv Card Electrophysiol. 2019. PMID: 30758702 Free PMC article. Clinical Trial.
Dabigatran dual therapy with ticagrelor or clopidogrel after percutaneous coronary intervention in atrial fibrillation patients with or without acute coronary syndrome: a subgroup analysis from the RE-DUAL PCI trial.
Oldgren J, Steg PG, Hohnloser SH, Lip GYH, Kimura T, Nordaby M, Brueckmann M, Kleine E, Ten Berg JM, Bhatt DL, Cannon CP. Oldgren J, et al. Among authors: nordaby m. Eur Heart J. 2019 May 14;40(19):1553-1562. doi: 10.1093/eurheartj/ehz059. Eur Heart J. 2019. PMID: 30793734 Free PMC article. Clinical Trial.
Relationship of stroke and bleeding risk profiles to efficacy and safety of dabigatran dual therapy versus warfarin triple therapy in atrial fibrillation after percutaneous coronary intervention: An ancillary analysis from the RE-DUAL PCI trial.
Lip GYH, Mauri L, Montalescot G, Ozkor M, Vardas P, Steg PG, Bhatt DL, Hohnloser SH, Miede C, Nordaby M, Brueckmann M, Kreuzer J, Kimura T, Oldgren J, Ten Berg JM, Cannon CP. Lip GYH, et al. Among authors: nordaby m. Am Heart J. 2019 Jun;212:13-22. doi: 10.1016/j.ahj.2019.02.006. Epub 2019 Mar 1. Am Heart J. 2019. PMID: 30928824 Clinical Trial.
Renal Function and Outcomes With Dabigatran Dual Antithrombotic Therapy in Atrial Fibrillation Patients After PCI.
Hohnloser SH, Steg PG, Oldgren J, Nickenig G, Kiss RG, Ongen Z, Navarro Estrada JL, Oude Ophuis T, Lip GYH, Nordaby M, Kleine E, Ten Berg JM, Bhatt DL, Cannon CP; RE-DUAL PCI Steering Committee and Investigators. Hohnloser SH, et al. Among authors: nordaby m. JACC Cardiovasc Interv. 2019 Aug 26;12(16):1553-1561. doi: 10.1016/j.jcin.2019.05.050. JACC Cardiovasc Interv. 2019. PMID: 31439336 Free article. Clinical Trial.
35 results